Takeda PharmaceuticalSee all their emails

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

A real announcement email from Takeda Pharmaceutical. Captured June 11, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations email from Takeda Pharmaceutical screenshot

Captured Announcement

Takeda Pharmaceutical announces positive Phase 3 clinical trial results for their new oral psoriasis treatment, Zasocitinib.

The email features a clean, corporate layout with a top logo, a branded header section with a red accent bar, a clear headline, date, and a 'Learn More' CTA. A feedback survey section is included above the footer.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.